Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positivemetastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial (vol 9, pg 197, 2023)

被引：0

作者：

Mao, Yuanjie ^{[1
,2
,4
]}

Zhong, Wenjun ^{[3
]}

机构：

[1] Ohio Univ, Diabet Inst, Athens, OH USA

[2] Ohio Hlth Castrop Ctr, Diabet & Endocrinol Clin, Athens, OH USA

[3] Merck & Co Inc, Merck Res Labs, West Point, PA USA

[4] Ohio Univ, Diabet Inst, Pk Hall 149, Athens, OH 45701 USA

来源：

JAMA ONCOLOGY | 2023年 / 9卷 / 02期

关键词：

D O I：

10.1001/jamaoncol.2022.7864

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：284 / 284

页数：1

共 50 条

[21] A randomized, double-blinded pivotal study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos. unresectable locally advanced or metastatic breast cancer: HER2CLIMB
Mueller, V.
Park-Simon, T. -W.
Huober, J.
Schmidt, M.
Weide, R.
Reinisch, M.
Fehm, T.
Salat, C.
Loibl, S.
Schem, C.
Winer, E.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 28 - 28
[22] Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)
Mueller, Volkmar
Wardley, Andrew
Paplomata, Elisavet
Hamilton, Erika
Zelnak, Amelia
Fehrenbacher, Louis
Jakobsen, Erik
Curtit, Elsa
Boyle, Frances
Brix, Eva Harder
Brenner, Andrew
Crouzet, Laurence
Ferrario, Cristiano
Munoz-Mateu, Montserrat
Arkenau, Hendrik-Tobias
Iqbal, Nayyer
Aithal, Sramila
Block, Margaret
Cold, Soeren
Cancel, Mathilde
Hahn, Olwen
Poosarla, Teja
Stringer-Reasor, Erica
Colleoni, Marco
Cameron, David
Curigliano, Giuseppe
Siadak, Muriel
DeBusk, Kendra
Ramos, Jorge
Feng, Wentao
Gelmon, Karen
EUROPEAN JOURNAL OF CANCER, 2021, 153 : 223 - 233
[23] A MULTICENTER PHASE 1 TRIAL OF TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER2 POSITIVE BREAST CANCER (TUTOR)
Ahluwalia, Manmeet
Ozair, Ahmad
Bardhan, Mainak
Bellur, Shreyas
Starosciak, Amy
Perche, Dilanis
Khosla, Atulya
Leon-Ariza, Daniel
Rubens, Muni
Odia, Yazmin
Mehta, Minesh
Kotecha, Rupesh
Mcdermott, Michael
Sandoval-Leon, Ana
Mahtani, Reshma
Peereboom, David
NEURO-ONCOLOGY, 2024, 26
[24] A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB)
Paplomata, E.
Bachelot, T.
Mueller, V.
Murias, C.
Murthy, R. K.
Okines, A. F. C.
Wardley, A. M.
Walker, L. N.
Antunes De Melo e Oliveira, A. M.
ANNALS OF ONCOLOGY, 2019, 30 : 63 - 64
[25] HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01)
[26] HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
Hurvitz, Sara
Loi, Sherene
O'Shaughnessy, Joyce
Okines, Alicia
Tolaney, Sara
Sohn, Joo Hyuk
Saura, Cristina
Zhu, Xiaofu
Cameron, David
Bachelot, Thomas
Hamilton, Erika
Curigliano, Giuseppe
Wolff, Antonio
Harbeck, Nadia
Masuda, Norikazu
Vahdat, Linda
Zaman, Khalil
Valdes-Albini, Frances
Block, Margaret
Pluard, Timothy
Tan, Tira
Gawryletz, Chelsea
Chan, Arlene
Bedard, Philippe
Yerushalmi, Rinat
Xu, Binghe
Tryfonidis, Konstantinos
Schmitt, Michael
Xie, Joan
Borges, Virginia
CANCER RESEARCH, 2024, 84 (09)
[27] A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB)
Anders, Carey K.
Murthy, Rashmi Krishna
Hamilton, Erika Paige
Borges, Virginia F.
Cameron, David A.
Carey, Lisa A.
Mueller, Volkmar
Curigliano, Giuseppe
Gelmon, Karen A.
Hortobagyi, Gabriel N.
Krop, Ian E.
Loibl, Sibylle
Pivot, Xavier B.
Pegram, Mark D.
Slamon, Dennis J.
Hurvitz, Sara A.
Tsai, Michaela L.
Winer, Eric P.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[28] A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)
Anders, Carey
Murthy, Rashmi
Hamilton, Erika
Borges, Virginia
Cameron, David
Carey, Lisa
Mueller, Volkmar
Curigliano, Giuseppe
Gelmon, Karen
Hortobagyi, Gabriel
Krop, Ian
Loibl, Sibylle
Pivot, Xavier
Pegram, Mark
Slamon, Dennis
Hurvitz, Sara
Tsai, Michaela
Winer, Eric
CANCER RESEARCH, 2017, 77
[29] Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer A Randomized Clinical Trial
Rugo, Hope S.
Barve, Abhijit
Waller, Cornelius F.
Hernandez-Bronchud, Miguel
Herson, Jay
Yuan, Jinyu
Sharma, Rajiv
Baczkowski, Mark
Kothekar, Mudgal
Loganathan, Subramanian
Manikhas, Alexey
Bondarenko, Igor
Mukhametshina, Guzel
Nemsadze, Gia
Parra, Joseph D.
Abesamis-Tiambeng, Maria Luisa T.
Baramidze, Kakhaber
Akewanlop, Charuwan
Vynnychenko, Ihor
Sriuranpong, Virote
Mamillapalli, Gopichand
Ray, Sirshendu
Yanez Ruiz, Eduardo P.
Pennella, Eduardo
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (01): : 37 - 47
[30] HER2CLIMB-04: phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+locally advanced or metastatic breast cancer with and without brain metastases (trial in progress)
Hamilton, Erika
Carey, Lisa
Ramos, Jorge
Chen, Yiyi
Krop, Ian
CANCER RESEARCH, 2022, 82 (04)

← 1 2 3 4 5 →